<DOC>
	<DOC>NCT02998450</DOC>
	<brief_summary>The purpose of this Phase 1a, first in human, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, PK and PD profile of the orally administered IMR-687 in healthy adult subjects.</brief_summary>
	<brief_title>A Study of IMR-687 in Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemoglobin SC Disease</mesh_term>
	<criteria>Be healthy as judged by the Investigator on the basis of prestudy tests performed at Screening, with healthy body mass index (BMI), healthy body weight, and laboratory results within normal laboratory reference range or determined not to be clinically significant by the Investigator; and be free from drugs of abuse. Females who are pregnant, trying to become pregnant, or breastfeeding; and males with female partners who are trying to conceive. Asthmatics or other individuals who use or may use albuterol rescue inhalers or nebulizers. A significant history of cardiovascular disease. On ECG, a QTcF &gt;450 ms or the presence of clinically significant abnormalities as determined by the Investigator. Elevated blood pressure. Use within 30 days prior to Day 1 of any inhibitors or substrates of targets of IMR687.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Sickle Beta 0 Thalassemia</keyword>
</DOC>